PSMA1 and ovarian carcinoma: To confirm the oncogenic phenotypes observed upon ZNF217 overexpression and to determine the utility of ZNF217 as a therapeutic target, we stably expressed shRNA targeting different regions of the ZNF217 mRNA in five different human ovarian cancer cell lines: OVCA420, TYK-Nu, OVCAR4, OVCAR3, and OVCAR8.